Seeking Alpha

Celgene's (CELG -0.2%) Apremilast treatment for psoriatic arthritis was effective in a Phase III...

Celgene's (CELG -0.2%) Apremilast treatment for psoriatic arthritis was effective in a Phase III trial and had no major safety problems. The study is the first of three trials of the drug, and Celgene expects to file for FDA approval in H1 next year. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)